Stuart Therapeutics has licensed the exclusive worldwide rights to collagen mimetic peptides (CMPs) of unique design, which mimic human collagen, for all human ophthalmic therapeutic applications. and have application in human and veterinary therapeutics and diagnostics. They have an amino acid sequence identical to a single strand of human type I collagen, and are non-immunogenic. The Stuart Therapeutics team has enhanced the value of these peptides by licensing additional patent filings for US and international patents that provide further protection for the technology in ophthalmology, and creating a novel therapeutic platform — PolyCol.

When used in ophthalmic clinical applications, PolyCol targets, anchors to and repairs damaged collagen, which is present in many diseases and trauma conditions. PolyCol can also chemically link to and deliver both small molecule therapeutics and biologics, enhancing their therapeutic outcomes, reducing dosage and frequency of administration. Stuart Therapeutics’ licenses and knowhow relating to PolyCol cover novel therapeutic compounds and their use in a variety of conditions.

PolyCol’s linking chemistry options offer a number of different bioavailability approaches for therapeutics, including extended release and delayed release. PolyCol’s composition, variations, and applications are more fully described in the Stuart Therapeutics white paper, “PolyCol, A New Topical Therapeutic,” which describes the science behind collagen, collagen mimetic peptides, and PolyCol, along with its proposed applications.

Stuart Therapeutics has completed a series of animal proof of concept tests that demonstrate the unique ability of PolyCol to accelerate the healing of damaged collagen in ocular surface conditions, suggesting that PolyCol has therapeutic benefit for many indications which include damaged collagen, including dry eye and corneal ulcers of any etiology. The therapeutic ST-100 is in pre-clinical development to address these ocular surface disease indications.